Provided by Tiger Fintech (Singapore) Pte. Ltd.

Altimmune, Inc.

5.17
+0.20004.02%
Volume:1.47M
Turnover:7.47M
Market Cap:398.16M
PE:-3.86
High:5.18
Open:4.97
Low:4.92
Close:4.97
Loading ...

Altimmune provided key pipeline updates with Q3 report, says B. Riley

TIPRANKS
·
14 Nov 2024

Altimmune’s pemvidutide looks differentiated among GLP-1s, says H.C. Wainwright

TIPRANKS
·
14 Nov 2024

Altimmune (ALT) Receives a Buy from Evercore ISI

TIPRANKS
·
13 Nov 2024

Daiichi Sankyo to Showcase TURALIO® Research in Patients with Tenosynovial Giant Cell Tumor at CTOS

Business Wire
·
13 Nov 2024

NRBO: Topline Results for Phase 2a Trial of DA-1241 in MASH Expected in December 2024

Zacks Small Cap Research
·
13 Nov 2024

Altimmune stock rallies 30% on business updates, UBS buy rating

seekingalpha
·
13 Nov 2024

Altimmune Inc reports results for the quarter ended September 30 - Earnings Summary

Reuters
·
12 Nov 2024

Altimmune Initiated at Buy by UBS

Dow Jones
·
12 Nov 2024

UBS Initiates Altimmune at Buy With $26 Price Target

MT Newswires Live
·
12 Nov 2024

Altimmune Q3 2024 GAAP EPS $(0.32) Beats $(0.36) Estimate, Sales $5.000K Beat $833.330 Estimate

Benzinga
·
12 Nov 2024

Altimmune initiated with a Buy at UBS

TIPRANKS
·
12 Nov 2024

Altimmune Names Greg Weaver Chief Financial Officer

MT Newswires Live
·
11 Nov 2024

Altimmune names Greg Weaver as CFO

seekingalpha
·
11 Nov 2024

BRIEF-Altimmune Appoints Life Sciences Industry Veteran Greg Weaver As Chief Financial Officer

Reuters
·
11 Nov 2024

BRIEF-Altimmune Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Reuters
·
11 Nov 2024

Altimmune Appoints Life Sciences Industry Veteran Greg Weaver as Chief Financial Officer

THOMSON REUTERS
·
11 Nov 2024

Altimmune Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

THOMSON REUTERS
·
11 Nov 2024

Altimmune Inc expected to post a loss of 35 cents a share - Earnings Preview

Reuters
·
09 Nov 2024

Calendar of U.S. Earnings Expected in the Week Ahead

Dow Jones
·
08 Nov 2024

Altimmune, FDA agree on efficacy measures for phase 3 trial of pemvidutide

seekingalpha
·
08 Nov 2024